Within the same market, the Types dimension classifies offerings into infrastructure‑as‑a‑service (IaaS), platform‑as‑a‑service (PaaS) and software‑as‑a‑service (SaaS) layers, each further divided into public, private, and hybrid deployment models. IaaS—primarily public cloud instances—provides raw compute, storage, and networking resources that enable laboratories to construct custom pipelines; its flexibility accounts for roughly 45 % of the spend on application‑driven workloads. PaaS solutions, such as managed workflow engines and container orchestration services, represent about 35 % of the market, offering standardized environments that reduce integration effort and improve reproducibility. SaaS products, delivered as turnkey analytics suites for genomics, proteomics, or imaging, capture the remaining 20 %, reflecting the premium placed on ready‑to‑use functionality and compliance certifications. The hybrid model, which combines on‑premise resources with cloud bursting, is embedded across all three types, allowing organizations to balance data‑ sovereignty with scalability. This market taxonomy demonstrates how service‑type selection directly influences cost structures and adoption rates across the Cell Biology Cloud Computing landscape.